BIIB:NGS-Biogen Inc. (USD)

EQUITY | Drug Manufacturers - General | Nasdaq Global Select

Last Closing

USD 213.2

Change

+1.31 (+0.62)%

Market Cap

USD 69.21B

Volume

1.83M

Analyst Target

USD 305.39
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

USD 257.50B
AMGN Amgen Inc

N/A

USD 174.29B
SNY Sanofi ADR

N/A

USD 141.45B
GILD Gilead Sciences Inc

N/A

USD 98.52B
GRFS Grifols SA ADR

N/A

USD 6.95B
AMRN Amarin Corporation PLC

N/A

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
SCLX Scilex Holding Company

N/A

N/A
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing BIIB

XYLU:LSE Global X S&P 500® Covere.. 6.55 % 0.00 %

N/A

USD 0.03B
UBIO 6.30 % 0.95 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 3.51 % 0.00 %

N/A

N/A
MRND 2.44 % 0.00 %

N/A

N/A
VCSH Vanguard Short-Term Corpo.. 0.08 % 0.07 %

N/A

USD 35.67B
SCHZ Schwab U.S. Aggregate Bon.. 0.01 % 0.04 %

N/A

USD 8.18B
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.45B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.09B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD 3.31M
FLAG 0.00 % 1.52 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.71B
MXDU 0.00 % 0.34 %

N/A

N/A
DQML 0.00 % 0.00 %

N/A

N/A
JAGG 0.00 % 0.07 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

N/A
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

USD 0.01B
XMWD:LSE Xtrackers MSCI World Swap.. 0.00 % 0.00 %

N/A

N/A
MVUS:PA 0.00 % 0.00 %

N/A

N/A
SPMV:PA 0.00 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
CEM2:F 0.00 % 0.00 %

N/A

N/A
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
CEM2:XETRA 0.00 % 0.00 %

N/A

N/A
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

N/A

USD 0.12B
BIOT 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
HEAL:SW iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.61% 40% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.61% 40% F 29% F
Trailing 12 Months  
Capital Gain -21.49% 56% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.49% 56% F 34% F
Trailing 5 Years  
Capital Gain -12.00% 43% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.00% 43% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain -1.01% 56% F 43% F
Dividend Return -1.01% 56% F 38% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.84% 44% F 70% C-
Risk Adjusted Return -4.07% 56% F 38% F
Market Capitalization 69.21B 50% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.00 100% 33%
Price/Book Ratio 1.95 50% 48%
Price / Cash Flow Ratio 21.31 50% 14%
Price/Free Cash Flow Ratio 17.22 25% 16%
Management Effectiveness  
Return on Equity 8.05% 75% 72%
Return on Invested Capital 5.61% 50% 69%
Return on Assets 4.86% 63% 85%
Debt to Equity Ratio 45.87% 83% 43%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector